Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-20

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidemiological studies are usually conducted in the general population in adults without complications or pathology at baseline. The results obtained are therefore often better designed for primary prevention use. The prediction of mortality risk in patients with complications and requiring hospital follow-up is less well known.

The study purpose is to determine a mortality risk profile in a hospital cohort of patients with pathologies associated with metabolic diseases.

Today the "multimaker" scores based on a panel of biomarkers - have significantly improved the discriminating power of prediction models existing in many pathologies. It is no longer a single biomarker that can improve risk prediction but a complete and cross-sectional profile that is sought after. We aim to establish a personalised mortality risk profile by combining clinical and biological parameters including metabolomics, genetics, transcriptomics and epigenomics by high throughput screening of biological samples.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Complications in Hypertension and Obesity

NCT00552292

Metabolic Syndrome Hypertension Obesity +2 more

UNKNOWN

The Reversal Intervention for Metabolic Syndrome Study

NCT01043770

Metabolic Syndrome

COMPLETED NA

Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

NCT00171548

Metabolic Syndrome

COMPLETED

Retrospective Analysis for Patients With Metabolic Syndrome

NCT06182618

Metabolic Syndrome

RECRUITING

Regional Observation of the Metabolic Syndrome

NCT00874952

Metabolic Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prediction of the onset of diabetes and metabolic complications, especially cardiovascular, renal, or hepatic, is a major challenge to optimize the management of this disease.

Teams from the University Hospital of Lille have developed the Integra cohort study to identify the clinical and biological determinants of the occurrence of these complications and the mortality of patients with metabolic disorders.

The aim of the study is to identify clinico-biological determinants that are able to predict the occurence of death, cardiovascular events as well as hepatic or nephrotic one.

Follow-up data will be collected from National System of Health Data (SNDS) where data concerning hospitalisations, medical consultations and treatments are registered.

Biological samples are collected at baseline for a large OMICs analysis (metabolomics, genetics, transcriptomics and epigenomics) that would feed our predictive scoring system.

This project will allow us to describe new models of prediction of metabolic diseases and its complications, and to offer adapted and personalised methods of management, which can slow the progression of the disease and improve its prognosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metabolic Patient

Patients with a metabolic desease, defined as

1. Metabolic Syndrom
2. Diabetic
3. Obese

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetic: antecedent - treatment - or glycemia\> = 1.26 g / dl - or HbA1C\> = 6.5% and or
* Obese: BMI\> = 30 and or
* Metabolic syndrome defined AND
* Patient having given written consent to participate in the study or collection of the consent of the witness
* Social insured patient (excluding AME)
* Patient willing to comply with all procedures of the study and its duration AND

Patient also presenting a pathology among:

* Cardiology:

* Coronary patient(history of myocardial infarction, coronary bypass, or coronary angioplasty or stenosis greater than 50% on an epicardial vessel documented on coronary angiography)
* Patient with systolic or diastolic heart failure
* Patient with atrial fibrillation
* Patient with aortic stenosis (Vmax\> 2.5 m / s)
* Patient with high blood pressure
* neurology:

* ischemic stroke
* intracerebral hemorrhage
* transient ischemic attack
* diabetology:

* Obesity without diabetes
* Diabetes T2
* T1 diabetes
* Monogenic Diabetes / MODY
* African Diabetes
* Diabetes secondary to pancreatopathy / liver cirrhosis
* Diabetes post transplantation / post immunotherapy
* Diabetes associated with Steinert's disease
* hepatology: hepatological pathology
* nephrology: nephrology

Exclusion Criteria

* Unscheduled hospitalization less than 3 months old
* Ongoing treatment :

* Cytotoxic chemotherapy
* Radiotherapy
* HIV and / or HCV and / or active HBV infection
* OMS score\> = 2
* Pregnant woman

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No